Molecular Partners AG (MOLN)
5.42
+0.22
(+4.23%)
USD |
NASDAQ |
Nov 21, 16:00
5.71
+0.29
(+5.35%)
After-Hours: 07:44
Molecular Partners Net Income (Quarterly): -18.97M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -18.97M |
June 30, 2024 | -16.68M |
March 31, 2024 | -12.96M |
December 31, 2023 | -22.32M |
September 30, 2023 | -12.95M |
June 30, 2023 | -17.79M |
March 31, 2023 | -15.96M |
December 31, 2022 | -18.11M |
September 30, 2022 | -13.79M |
Date | Value |
---|---|
June 30, 2022 | -4.686M |
March 31, 2022 | 165.78M |
December 31, 2021 | -19.43M |
September 30, 2021 | -13.41M |
June 30, 2021 | -18.68M |
March 31, 2021 | -18.30M |
December 31, 2020 | -23.86M |
September 30, 2020 | -17.89M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-23.86M
Minimum
Dec 2020
165.78M
Maximum
Mar 2022
-5.882M
Average
-17.79M
Median
Jun 2023
Net Income (Quarterly) Benchmarks
AC Immune SA | 6.364M |
CRISPR Therapeutics AG | -85.94M |
Addex Therapeutics Ltd | 14.24M |
NLS Pharmaceutics Ltd | -- |
MoonLake Immunotherapeutics | -35.39M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 0.7875M |
Total Expenses (Quarterly) | 17.66M |
EPS Diluted (Quarterly) | -0.5666 |
Enterprise Value | 28.94M |
Profit Margin (Quarterly) | -2.41K% |
Earnings Yield | -39.51% |
Normalized Earnings Yield | -37.39 |